These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23061697)

  • 1. Rules for identifying potentially reactive or promiscuous compounds.
    Bruns RF; Watson IA
    J Med Chem; 2012 Nov; 55(22):9763-72. PubMed ID: 23061697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of triaging in determining the quality of output from high-throughput screening.
    Jones P; McElroy S; Morrison A; Pannifer A
    Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
    [No Abstract]   [Full Text] [Related]  

  • 4. Can we discover pharmacological promiscuity early in the drug discovery process?
    Peters JU; Hert J; Bissantz C; Hillebrecht A; Gerebtzoff G; Bendels S; Tillier F; Migeon J; Fischer H; Guba W; Kansy M
    Drug Discov Today; 2012 Apr; 17(7-8):325-35. PubMed ID: 22269136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the relationship between topology and selectivity for druglike molecules.
    Yang Y; Chen H; Nilsson I; Muresan S; Engkvist O
    J Med Chem; 2010 Nov; 53(21):7709-14. PubMed ID: 20942392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harvesting classification trees for drug discovery.
    Yuan Y; Chipman HA; Welch WJ
    J Chem Inf Model; 2012 Dec; 52(12):3169-80. PubMed ID: 23110407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scopy: an integrated negative design python library for desirable HTS/VS database design.
    Yang ZY; Yang ZJ; Lu AP; Hou TJ; Cao DS
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32892221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity-aware clustering of high throughput screening data and elucidation of orthogonal structure-activity relationships.
    Lounkine E; Nigsch F; Jenkins JL; Glick M
    J Chem Inf Model; 2011 Dec; 51(12):3158-68. PubMed ID: 22098146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.
    Shun TY; Lazo JS; Sharlow ER; Johnston PA
    J Biomol Screen; 2011 Jan; 16(1):1-14. PubMed ID: 21160066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds.
    Peters JU; Schnider P; Mattei P; Kansy M
    ChemMedChem; 2009 Apr; 4(4):680-6. PubMed ID: 19266525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the Degree of Promiscuity of Extensively Assayed Compounds.
    Jasial S; Hu Y; Bajorath J
    PLoS One; 2016; 11(4):e0153873. PubMed ID: 27082988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results.
    Popa-Burke IG; Issakova O; Arroway JD; Bernasconi P; Chen M; Coudurier L; Galasinski S; Jadhav AP; Janzen WP; Lagasca D; Liu D; Lewis RS; Mohney RP; Sepetov N; Sparkman DA; Hodge CN
    Anal Chem; 2004 Dec; 76(24):7278-87. PubMed ID: 15595870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
    Baell JB; Holloway GA
    J Med Chem; 2010 Apr; 53(7):2719-40. PubMed ID: 20131845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput assays for promiscuous inhibitors.
    Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
    Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.